A substantial proportion of stroke survivors have cognitive deficits ranging from mild cognitive impairment (PS-MCI) to dementia.
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to Establish a Registry for Alzheimer's Disease (CERAD)-plus battery as previously suggested. 9 Z scores were calculated from an agematched healthy control group database.
All patients were asked to undergo amyloid PET. Images were acquired on a GE Discovery PET/computed tomographic scanner using flutemetamol (   18   F) 10 ( Figure 1 ). For quantitative analyses, gray matter volumes of interest (VOIs) were applied to individual MRI and transferred to the coregistered PET images using PMOD V3.407 (PMOD Technologies Ltd, Zurich, Switzerland). A composite VOI including frontal, parietal, lateral temporal, and occipital cortex, as well as the posterior cingulate, was created and the corresponding standardized uptake value ratios (SUVR) were calculated with the cerebellar cortex as a reference. To avoid a confounding influence by the stroke lesion, the lesion was delineated on the corresponding MRI and excluded from the composite VOI on the PET data set. SUVR data were used for correlational analyses but not for binary visual rating because a widely accepted threshold for flutemetamol (18F) positivity is still missing. 11 To calculate SUVs of the peri-infarct region, VOIs were drawn manually around the stroke lesion on the fluid attenuated inversion recovery images-weighted MRI. Reference VOIs were obtained from corresponding regions in the contralateral hemisphere ( Figure I in the online-only Data Supplement).
The study was approved by the local institutional review board. Written informed consent was obtained before study inclusion. Detailed methods are provided in the online-only Data Supplement.
Statistical Analyses
Correlations between cognitive variables and SUVR were evaluated by logistic regression using age, sex, and years of education as covariates. Group differences were calculated using WilcoxonMann-Whitney test. Statistical analysis was performed with SAS version 9.3.
Results
Fifty-six (37%) of the 153 patients with stroke who returned for a follow-up visit 6 months after stroke agreed to undergo amyloid PET ( Figure II in the online-only Data Supplement). Their demographic and clinical characteristics were similar to those of the remaining study cohort (Table I in the online-only Data Supplement). Three of the 153 patients who returned for follow-up (2%) developed new onset dementia. None of them underwent amyloid imaging. Thirty-eight (68%) of the 56 patients with stroke who consented to amyloid PET were classified as PS-MCI (Table) . 
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Demographic variables, educational status, and infarct characteristics of these PS-MCI patients did not differ when compared with cognitively healthy patients with amyloid PET (Table II in 
Discussion
This study shows that in the majority of PS-MCI patients, cognitive deficits develop in the absence of amyloid pathology. Also, there was no indication of a correlation between amyloid deposition and cognitive scores in quantitative analyses. Hence, factors other than amyloid pathology likely contribute to the development of PS-MCI. A recent study in Chinese patients with stroke or transient ischemic attack found amyloid PET positivity in 30% of patients with incident dementia.
12 However, the mean age of incident cases was 80 years, and the point estimate for amyloid positivity in cognitively healthy subjects aged 80 years has been demonstrated to be 33%, so similar. 13 In the current study, the prevalence of amyloid positivity in PS-MCI patients was below the point estimate for cognitively healthy subjects of similar age. Of note, patients receiving amyloid imaging resembled those without amyloid imaging with respect to baseline characteristics and the prevalence of cognitive impairment (Tables I through III in the online-only Data Supplement). Thus, our results can be considered representative of our overall cohort. Collectively, these findings add to the notion that the prevalence of amyloid pathology in poststroke cognitive impairment is very low, 14 thus emphasizing the role of vascular factors in this group of patients. Nevertheless, a recent study by Liu et al 15 suggests, that if present, amyloid positivity may be associated with a more rapid cognitive decline.
We found no amyloid retention in the peri-infarct region 6 months after stroke, and the infarct area was systematically excluded from quantification of amyloid. Hence, our results are unlikely to be influenced by infarct characteristics. Limitations include those inherent to PET studies, in particular the small sample size. Also, none of the patients who developed new onset dementia underwent PET imaging. Hence, our findings are not generalizable to patients with poststroke dementia. Studies with long-term follow-up are required to determine the prognostic value of amyloid-PET in PS-MCI patients.
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SUPPLEMENTAL MATERIAL
Study population
Patients were recruited between 05/2011 and 09/2014 through the ongoing prospective observational "DEterminants of DEMentia After Stroke (DEDEMAS) study" (NCT01334749). The full study protocol is published elsewhere. 1 The main inclusion criterion was an acute stroke defined by an acute focal neurological deficit in combination with a corresponding lesion on MRI. Main exclusion criteria were i) a stroke going back more than 72 hours; ii) pre-stroke dementia as defined by a summed score of >64 in the short version of the "Informant Questionnaire on Cognitive decline in the Elderly" (IQCODE); 2 and iii) malignant disease resulting in a life expectancy less than three years. Follow-up visits 6 months after stroke encompassed a second standardized 3Tesla-MRI scan and comprehensive cognitive testing including the extended "Consortium to Establish a Registry for Alzheimer's Disease" (CERAD-Plus) -neuropsychologicalbattery. 3 For MCI diagnosis, patients had to be impaired (z-score <-1.5) in the CERAD-plus battery as previously suggested. 4 Z-scores were calculated from an age-matched healthy control group database.
3 Among 178 patients who completed the baseline visit, 153 (86%) returned for a follow-up visit after 6 months (suppl. fig.I ). All of them were asked to undergo flutemetamol ( 18 F) imaging at the follow-up visit irrespective of reported memory deficits. 56 of the 153 patients (37%) with personal visit agreed. Main reasons for refusal were fear of radiation exposure, unwillingness to spend extra time on the procedure, inconvenience imposed by the procedure, and concerns to learn about the PET results. Three patients developed incident PSD within the 6 month interval after stroke. All of them refused to undergo amyloid PET (suppl. table III).
MR-Imaging
All patients received standardized MR imaging on a single 3 Tesla system with a 32-channel head coil (Magnetom Verio, Siemens Medical Systems, Erlangen, Germany) as described. 1 Infarcts were identified on trace images from diffusion tensor imaging with repetition time (TR)/echo time (TE) = 12700/81 ms, 30 diffusion encoding directions, a b-value of 1000 s/mm2, two averages, 2 x 2 mm in-plane resolution and 2mm slice thickness (no interslice gap). Three-dimensional fluid attenuated inversion recovery (FLAIR) images for the discovery of white matter hyperintensities were obtained using TR/TE/inversion time (TI) = 5000/395/1800 ms and 1 mm isotropic 3D acquisition. Hemorrhages were identified on the admission CT scans and confirmed on gradient echo MRI.
PET-Imaging
PET images were acquired on a GE Discovery 690 PET/CT scanner using a 3-dimensional mode. A low-dose CT scan was performed for attenuation correction. Amyloid imaging in all patients was done using flutemetamol (18F), 5 as shown in figure 1.
After intravenous injection of 183 ± 2 MBq flutemetamol (18F) static image data were acquired from 90 min to 110 min. PET-data were reconstructed iteratively. 2 The visual assessment was performed using a previously validated protocol. 6 Specifically, all PET images were interpreted by three independent readers (S.D., P.B., A.R.), which were all blinded with regard to the clinical information. Readers had been trained using a DVD-based program. Images were reviewed in color, using a rainbow color scale. The readers were trained to assess the following regions for 18F-flutemetamol activity: frontal, posterior cingulate/precuneus, lateral temporal, inferior parietal, and striatal. Positive images were defined as having at least one cortical region with reduction or loss of the normally distinct gray matter-white matter contrast, that is, one or more regions with increased gray matter (50%-60% intensity) or reduced white matter contrast. We used the majority visual read results, i.e. the scan classification on which at least two readers agreed. The majority read result was necessary in two subjects. Otherwise, there was consensus among all three readers.
Visual assessment and binary rating as amyloid-positive or -negative has previously been validated by histopathological data 6 and reflects the appropriate use criteria for amyloid PET imaging as recommended by a recent expert statement. 7 For quantitative analyses grey matter volumes of interest (VOIs) were applied to individual MR images and transferred to the co-registered PET images using PMOD V3.407 (PMOD Technologies Ltd., Zurich, Switzerland). A composite VOI including frontal, parietal, lateral temporal and occipital cortex as well as the posterior cingulate was created and the corresponding standardized uptake value ratios (SUVR) were calculated with the cerebellar cortex as a reference. To avoid a confounding influence by the stroke lesion, the lesion was delineated on the corresponding MRI and consecutively excluded from the composite VOI on the PET dataset. SUVR data was used for correlational analyses regarding cognitive testing but not for binary visual rating as a widely accepted threshold for flutemetamol (18F) positivity is still missing. 6 To calculate a specific SUVR within the peri-infarct region, a VOI was drawn visually around the stroke lesion on a FLAIR weighted MRI image. Then a mirrored region of interest was applied in the contralateral hemisphere for reference values (suppl. fig.  I ). Follow-up n=153 drop out, n= 25  refused follow-up, n=11  no personal visit possible but agreed to telephone interview, n=6  no personal visit possible but answered questionnaire, n=1  died, n= 4  institutionalized, not able to attend interview, n=2  alive (information from the registry office register) but could not be contacted, n=1
Suppl.
Amyloid-PET n=56 refused PET, n= 97 reasons for refusing PET (n not further specified)  fear of radiation  unwillingness to spend extra time on the procedure  inconvenience imposed by procedure  concerns to learn about the results
